Vaso-occlusive Crisis Clinical Trial
Official title:
Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease With Vaso-occlusive Crisis and Morphinic Treatment
Acute chest syndrome is a severe respiratory complication of sickle cell disease.
The standard prevention of this dangerous complication is spirometry in wich patient is
required to take deep breaths trough a little device several times a day. This treatment is
compromised when pain in important or when the patient is asleep and cannot participate.
The investigators hypothesised that non invasive ventilation in wich patient have no effort
to take might be a better prevention than spirometry and may improve pain and quality of
sleep.
Children with vaso-occlusive crisis necessitating morphinic treatment will be randomly
assigned with either spirometry or ventilation and the investigators will monitor for
occurrence of acute chest syndrome, pain and quality of sleep.
Acute chest syndrome is a severe complication of sickle cell disease. Several factors can
contribute to this complication including infections, vaso-occlusive crisis, important pain
that may give shortness of breath and morphinic treatments as they may cause
hypoventilation.
The standard prevention of this dangerous complication is incentive spirometry in wich
patient is required to take deep breaths trough a little device several times a day. This
treatment is compromised when pain in important or when the patient is asleep and cannot
participate.
In patients who have had surgery who have also pain and morphinic treatments, non invasive
ventilation have proven a good option for preventing pulmonary complications.
Besides, our experience in non invasive ventilation for treatment of acute chest syndrome
show a good tolerance and efficiency. It also seems to help with pain management.
The investigators hypothesised that non invasive ventilation in wich patient have no effort
to take might be a better prevention than incentive spirometry and may improve pain and
quality of sleep.
After informed consent, patients aged from 6 to 20 years old with SS or S-Beta sickle cell
disease with vaso-occlusive crisis necessitating morphinic treatment hospitalised in
intensive care unit in Necker Hospital for Sick Children (Paris) will be randomly assigned
with either spirometry or ventilation. It is a monocentric study.
Patients with acute chest syndrome, oxygen needs, pneumonia or other condition requiring
ventilation at presentation will not be included.
Spirometry will be realised through volumetric devices, every two hours during the day with
10 maximum inspirations and at night if the patient is awake.
Non invasive ventilation will be applied through a nasal mask with VS III machines from
Resmed®, at least one hour every four hour but may be maintained more if the patient chooses
to or is asleep with the machine on.
The investigators will monitor for occurrence of acute chest syndrome, pain, morphinic
requirements, length of hospital stay, comfort, quality of sleep The treatment will be
continued until morphinic treatment is stopped. The investigators intend to include 60
patients in each arm to show a difference of 25% in the occurrence of acute chest syndrome
(primary judgement criteria).
Acute chest syndrome will be defined according to the criteria used by Vichinsky (Vichinsky,
E. P. et al. Acute chest syndrome in sickle cell disease: clinical presentation and course.
Cooperative Study of Sickle Cell Disease. Blood 89, 1787-1792 (1997) The investigators will
aslo compare morphinic requirements, length of hospital stay and quality of sleep as
secondary judgment criteria.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03639805 -
Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis
|
N/A | |
Withdrawn |
NCT00711698 -
Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)
|
Phase 2 | |
Recruiting |
NCT05289700 -
Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)
|
Phase 3 | |
Recruiting |
NCT03412045 -
Hyperbaric Oxygen Therapy in Sickle Cell Pain
|
N/A | |
Recruiting |
NCT05376046 -
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
|
||
Active, not recruiting |
NCT04935879 -
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
|
Phase 3 | |
Terminated |
NCT01891812 -
Nitrous Oxide Analgesia Vaso-occlusive Crisis
|
Phase 2 | |
Completed |
NCT04301336 -
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
|
Phase 2/Phase 3 | |
Completed |
NCT01737814 -
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
|
Phase 3 | |
Completed |
NCT01419977 -
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
|
Phase 2 | |
Completed |
NCT01119833 -
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
|
Phase 2 | |
Not yet recruiting |
NCT06181695 -
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric
|
Phase 3 | |
Recruiting |
NCT05378555 -
Oral Ketamine for Treatment of Vaso-Occlusive Pain
|
Phase 3 | |
Completed |
NCT04756375 -
Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room
|
N/A | |
Active, not recruiting |
NCT05348915 -
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
|
Phase 3 | |
Enrolling by invitation |
NCT06345638 -
Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
|
||
Completed |
NCT03296345 -
Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
|
Phase 2 | |
Terminated |
NCT02179177 -
Apixaban in Patients With Sickle Cell Disease
|
Phase 3 | |
Recruiting |
NCT03353584 -
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
|
N/A | |
Terminated |
NCT01522196 -
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
|
Phase 2 |